Entrada Therapeutics, Inc.
US ˙ NasdaqGM ˙ US29384C1080

SecurityTRDA / Entrada Therapeutics, Inc.
InstitutionQube Research & Technologies Ltd
Latest Disclosed Ownership87,453 shares
Latest Disclosed Value $ 1,103,657
Qube Research & Technologies Ltd reports 50.32% decrease in ownership of TRDA / Entrada Therapeutics, Inc.

On May 15, 2026 - Qube Research & Technologies Ltd filed a 13F-HR form disclosing ownership of 87,453 shares of Entrada Therapeutics, Inc. (US:TRDA) valued at $1,103,657 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 176,018 shares of Entrada Therapeutics, Inc.. This represents a change in shares of -50.32% during the quarter. The current value of the position is $575,441 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F ENTRADA THERAPEUTICS COM 29384C108 87,453 -88,565 -50.32 1,104 -39.03 0.0012
2026-02-17 2025-12-31 13F ENTRADA THERAPEUTICS COM 29384C108 176,018 -111,855 -38.86 1,809 8.39 0.0018
2025-11-14 2025-09-30 13F ENTRADA THERAPEUTICS COM 29384C108 287,873 154,143 115.26 1,670 85.86 0.0017
2025-08-14 2025-06-30 13F ENTRADA THERAPEUTICS COM 29384C108 133,730 108,737 435.07 899 299.11 0.0009
2025-05-15 2025-03-31 13F ENTRADA THERAPEUTICS COM 29384C108 24,993 24,993 226 0.0003
2023-08-14 2023-06-30 13F ENTRADA THERAPEUTICS COM 29384C108 0 -38,782 -100.00 0 -100.00
2023-05-15 2023-03-31 13F ENTRADA THERAPEUTICS COM 29384C108 38,782 22,000 131.09 562 148.67 0.0024
2023-02-14 2022-12-31 13F ENTRADA THERAPEUTICS COM 29384C108 16,782 16,782 227 0.0012
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.